Item 2.02 Results of Operations and Financial Condition.
On January 24, 2023, KemPharm, Inc. (the "Company") issued a letter to
shareholders (the "Letter"), in which the Company announced that as of December
31, 2022, the Company's cash, cash equivalents and long-term investments were
$102.9 million. The Letter is attached to this Current Report on Form 8-K
("Current Report") as Exhibit 99.1.
The foregoing cash, cash equivalents and long-term investments information is
based on preliminary unaudited information and management estimates for the year
ended December 31, 2022, is not a comprehensive statement of the Company's
financial results as of and for the fiscal year ended December 31, 2022, and is
subject to completion of the Company's financial closing procedures. The
Company's independent registered public accounting firm has not conducted an
audit or review of, and does not express an opinion or any other form of
assurance with respect to, this preliminary estimate.
The information contained in this item, including Exhibit 99.1, is being
furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such
filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements
contained in this Current Report that do not relate to matters of historical
fact should be considered forward-looking statements, including without
limitation statements regarding the Company's preliminary unaudited cash
position as of December 31, 2022. Statements using words such as "expect",
"anticipate", "believe", "may", "will" and similar terms are also
forward-looking statements. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other
important factors that may cause the Company's actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements, including,
but not limited to, the important factors discussed in detail in the "Risk
Factors" section of the Company's Annual Report on Form 10-K for the year ended
December 31, 2021, as updated by its Quarterly Report on Form 10-Q for the three
months ended September 30, 2022, and its other filings with the Securities and
Exchange Commission. Except as required by law, the Company undertakes no
obligations to make any revisions to the forward-looking statements contained in
this Current Report or to update them to reflect events or circumstances
occurring after the date of this Current Report, whether as a result of new
information, future developments or otherwise.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Letter to Shareholders, dated January 24, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses